Rosiglitazone–containing Medicines (Avandia/Avandamet) – Direct Healthcare Professional Communication issued by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 28/07/2010

 

Problem Or Issue:
Further to previous regulatory updates on cardiovascular risk with rosiglitazone, the Irish Medicines Board has issued a Direct Healthcare Professional Communication reinforcing existing recommendations about the use of rosiglitazone (Avandia/Avandamet) in the treatment of diabetes. The communication also provides information about new data currently being evaluated at EU level concerning rosiglitazone and cardiovascular risk. 

Rosiglitazone Direct Healthcare Professional Communication


« Back